Dr. Tom Mikkelsen
Address: 1 Ford Pace, Detroit, Michigan, 48202, United States, Wayne State University
Gender: Male
About the Doctor / Professional
Biographical Statement:
Internationally recognized in the neuro-oncology and precision medicine areas, Dr. Mikkelsen received his MD from the University of Calgary, Canada and completed clinical training in neurology at the Montreal Neurologic Institute. Following this, he did post-doctoral training in brain tumor cellular and molecular biology at the Ludwig Institute for Cancer Research in Montreal and then in La Jolla, California.
Philosophy
The internet age has been empowering for many patients dealing with a new diagnosis of a brain tumor. However, there is way too much unfiltered content and it takes a real multidisciplinary team to partner with a patient and their family to formulate the best plan of care. We have access to many novel and innovative approaches to treatment to compliment current state-of-the-art treatment. The goal, of course, is to maximize the quality of a person's life, despite the challenges. This means emotionally, mentally and physically. I pride myself on engaging a patient, the team and moving ahead in the most promising way possible.
Research Interests
Hermelin Brain Tumor Bank and Personalized Brain Tumor Therapy: HBTC is a leader in the understanding of the genetics of brain tumors, and in the development of therapies matched to each patient's brain tumor genetics for the best chance at recovery. The Center is a major contributor to The Cancer Genome Atlas (TCGA) - a national cooperative of major academic medical centers sponsored by the National Institutes of Health, responsible for identifying certain survival-related genes. The data generated from the TCGA and the 1000 tumor tissues in the tumor bank are a major resource for each of the HBTC's research laboratories. HBTC resources constitute some 40% of resources in the national TCGA program.
Brain Tumor Neuro-imaging: Dr. Mikkelsen's laboratory has collaborated extensively with small animal imaging, clinical neuroradiology, and image analysis for pre-clinical and clinical brain tumor studies, primarily using perfusion CT and multiple MRI techniques. The long-term goal is to validate imaging biomarkers as measures of therapeutic response toward targeted therapies.
Dr. Mikkelsen works closely with Dr. Tobias Walbert and Dr. Jim Snyder, neuro-oncology colleagues, with clinical research interests focus on outcomes research.
Degree: University of Calgary 1983
Residency: Ludwig Institute For Cancer Research, Cellular and Molecular Biology, NY, 1992
- He has had an accomplished 23-year career with Henry Ford Health System, where he co-founded and managed the Hermelin Brain Tumor Center (HBTC), including the brain tumor biorepository - an internationally recognized resource for biospecimens and the clinical annotation associated with them, for more than 20 years.
- He has a long track record in clinical trials for both cancer and neurologic disorders, including as president and chief scientific officer at the Ontario Brain Institute.
- Dr. Mikkelsen currently serves as the medical director of the HFHS Precision Medicine and Clinical Trials Program.
- Additional (Examined) Certification, United Council of Neurologic Subspecialties of NeuroOncology (2012)
- Author of 175 publications and co-editor of a text book on brain tumor invasion
- “Top Doc”, HOUR Detroit (2003, 2004, 2005, 2006 & 2007)
- Best Doctors for Oncology, HOUR Detroit (2007 and 2008)
- Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas.
- The Immune Landscape of Cancer.
- Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment.
- Comprehensive Characterization of Cancer Driver Genes and Mutations.
- Oncogenic Signaling Pathways in The Cancer Genome Atlas.
- Pathogenic Germline Variants in 10,389 Adult Cancers.
- The somatic genomic landscape of glioblastoma.
- New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs.
- Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients.
- Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation.
- Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas.
- Genomic and Functional Approaches to Understanding Cancer Aneuploidy.
- Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma.
- A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers.
- An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics.
- Discordant inheritance of chromosomal and extrachromosomal DNA elements contributes to dynamic disease evolution in glioblastoma.
- The Immune Landscape of Cancer.
- Comprehensive Characterization of Cancer Driver Genes and Mutations.
- lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer.
- Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer.
- First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.
- Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas.
- The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma.
- Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer.
- A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples.
- Driver Fusions and Their Implications in the Development and Treatment of Human Cancers.
- Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment.
- Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas.
- Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images.
- Systematic Analysis of Splice-Site-Creating Mutations in Cancer.
- A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-β Superfamily.
- Comprehensive genomic characterization defines human glioblastoma genes and core pathways.
- Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics.
- The integrated landscape of driver genomic alterations in glioblastoma.
- Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.
- A Distinct DNA Methylation Shift in a Subset of Glioma CpG Island Methylator Phenotypes during Tumor Recurrence.
- Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers.
- Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study.
- Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas.
- Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types.
- Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma.
- Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC.
- Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types.
- The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma.
- Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas.
- Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma.
- Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.
- Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context.
- Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines.
- Correction to: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy.
- Transforming fusions of FGFR and TACC genes in human glioblastoma.
- Pan-cancer analysis of whole genomes.
- Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.
- Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy.
- Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution.
- Repurposing phenformin for the targeting of glioma stem cells and the treatment of glioblastoma.
- NRG oncology RTOG 0625: a randomized phase II trial of bevacizumab with either irinotecan or dose-dense temozolomide in recurrent glioblastoma.
- Phase II Study of Iniparib with Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma.
- Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis.
- Presenting signs and symptoms in brain tumors.
- Role of MRI in primary brain tumor evaluation.
- Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma.
- Brain-CODE: A Secure Neuroinformatics Platform for Management, Federation, Sharing and Analysis of Multi-Dimensional Neuroscience Data.
- Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy.
- Wen PY, Drappatz J, de Groot J, Prados MD, Reardon DA, Schiff D, Chamberlain M, Mikkelsen T, Desjardins A, Holland J, Ping J, Weitzman R, Cloughesy TF.
- Patient-derived glioblastoma cultures as a tool for small-molecule drug discovery.
- Through the patient's eyes: the value of a comprehensive brain tumor center.
- Targeting integrins in malignant glioma.
- Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working Group.
- Developing a brain tumor center.
- Recurrent high-grade glioma: a diagnostic and therapeutic challenge.
- Optimization of Glioblastoma Mouse Orthotopic Xenograft Models for Translational Research.
- Predictors of Venous Thromboembolism in Patients with Glioblastoma.
- An extended vascular model for less biased estimation of permeability parameters in DCE-T1 images.
- A parametric model of the brain vascular system for estimation of the arterial input function (AIF) at the tissue level.
- Big Data Needs Big Governance: Best Practices From Brain-CODE, the Ontario-Brain Institute's Neuroinformatics Platform.
- CXCR4 increases in-vivo glioma perivascular invasion, and reduces radiation induced apoptosis: A genetic knockdown study.
- High-Throughput Screening of Patient-Derived Cultures Reveals Potential for Precision Medicine in Glioblastoma.
- MRI-Tracked Tumor Vascular Changes in the Hours after Single-Fraction Irradiation.
- Treatment induced necrosis versus recurrent/progressing brain tumor: going beyond the boundaries of conventional morphologic imaging.
- Direct contact with perivascular tumor cells enhances integrin αvβ3 signaling and migration of endothelial cells.
- Burgett ME, Lathia JD, Roth P, Nowacki AS, Galileo DS, Pugacheva E, Huang P, Vasanji A, Li M, Byzova T, Mikkelsen T, Bao S, Rich JN, Weller M, Gladson CL.
- Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O6-Methylguanine-DNA Methyltransferase Biomarker Analyses.
- RTVP-1 promotes mesenchymal transformation of glioma via a STAT-3/IL-6-dependent positive feedback loop.
- The role of prophylactic anticonvulsants in the management of brain metastases: a systematic review and evidence-based clinical practice guideline.
- The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline.
- Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme.
- Reardon DA, Nabors LB, Stupp R, Mikkelsen T.
- DCE-MRI prediction of survival time for patients with glioblastoma multiforme: using an adaptive neuro-fuzzy-based model and nested model selection technique.
- Reproducibility and relative stability in magnetic resonance imaging indices of tumor vascular physiology over a period of 24h in a rat 9L gliosarcoma model.
- The role of retreatment in the management of recurrent/progressive brain metastases: a systematic review and evidence-based clinical practice guideline.
- A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma.
- The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline.
- The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline.
- Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients.
- A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients.
- The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline.
- Combination of vatalanib and a 20-HETE synthesis inhibitor results in decreased tumor growth in an animal model of human glioma.
- Identification of regions of normal grey matter and white matter from pathologic glioblastoma and necrosis in frozen sections using Raman imaging.
- Raman molecular imaging of brain frozen tissue sections.
- Phase I study of iniparib concurrent with monthly or continuous temozolomide dosing schedules in patients with newly diagnosed malignant gliomas.
- Proteomic comparison of oligodendrogliomas with and without 1pLOH.
- The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline.
- Related to testes-specific, vespid and pathogenesis protein-1 is regulated by methylation in glioblastoma.
- Model selection for DCE-T1 studies in glioblastoma.
- Phase II trial of sunitinib as adjuvant therapy after stereotactic radiosurgery in patients with 1-3 newly diagnosed brain metastases.
- Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study.
- Phase I study of GRN1005 in recurrent malignant glioma.
- Cilengitide induces autophagy-mediated cell death in glioma cells.
- The Corpus Callosum Wallerian Degeneration in the Unilateral Brain Tumors: Evaluation with Diffusion Tensor Imaging (DTI).
- SCA 17 phenotype with intermediate triplet repeat number.
- Peritumoral tissue compression is predictive of exudate flux in a rat model of cerebral tumor: an MRI study in an embedded tumor.
- Phase 2 study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma.
- A prognostic gene expression signature in infratentorial ependymoma.
- An integrative approach for in silico glioma research.
- Sox2 promotes malignancy in glioblastoma by regulating plasticity and astrocytic differentiation.
- Addition of MR imaging features and genetic biomarkers strengthens glioblastoma survival prediction in TCGA patients.
- Phase I study of terameprocol in patients with recurrent high-grade glioma.
- Intratumor distribution and test-retest comparisons of physiological parameters quantified by dynamic contrast-enhanced MRI in rat U251 glioma.
- Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab.
- Angiogenesis in glioma: molecular mechanisms and roadblocks to translation.
- Genomic mapping and survival prediction in glioblastoma: molecular subclassification strengthened by hemodynamic imaging biomarkers.
- Prediction of glioblastoma multiform response to bevacizumab treatment using multi-parametric MRI.
- Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus The cyclin-like protein Spy1 regulates growth and division characteristics of the CD133+ population in human glioma.
- Predicting survival in glioblastomas using diffusion tensor imaging metrics.
- Odyssey of hope: a physician's guide to communicating with brain tumor patients across the continuum of care.
- Segmentation of corpus callosum using diffusion tensor imaging: validation in patients with glioblastoma.
- Glioblastoma cell enrichment is critical for analysis of phosphorylated drug targets and proteomic-genomic correlations.
- Raman spectroscopy to distinguish grey matter, necrosis, and glioblastoma multiforme in frozen tissue sections.
- Subcurative radiation significantly increases cell proliferation, invasion, and migration of primary glioblastoma multiforme in vivo.
- MR imaging predictors of molecular profile and survival: multi-institutional study of the TCGA glioblastoma data set.
- DW-MRI as a biomarker to compare therapeutic outcomes in radiotherapy regimens incorporating temozolomide or gemcitabine in glioblastoma.
- Integrated morphologic analysis for the identification and characterization of disease subtypes.
- MicroRNA-137 is downregulated in glioblastoma and inhibits the stemness of glioma stem cells by targeting RTVP-1.
- Histological predictors of outcome in ependymoma are dependent on anatomic site within the central nervous system.
- Aurora A is differentially expressed in gliomas, is associated with patient survival in glioblastoma and is a potential chemotherapeutic target in gliomas.
- A nano-sized PARACEST-fluorescence imaging contrast agent facilitates and validates in vivo CEST MRI detection of glioma.
- Double minute chromosomes in glioblastoma multiforme are revealed by precise reconstruction of oncogenic amplicons.
- The induction of autophagy by gamma-radiation contributes to the radioresistance of glioma stem cells.
- Morphologic MRI features, diffusion tensor imaging and radiation dosimetric analysis to differentiate pseudo-progression from early tumor progression.
- Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency.
- Tumor-infiltrating lymphocytes in glioblastoma are associated with specific genomic alterations and related to transcriptional class.
- MicroRNA-145 is downregulated in glial tumors and regulates glioma cell migration by targeting connective tissue growth factor.
- Prognostic vascular imaging biomarkers in high-grade gliomas: tumor permeability as an adjunct to blood volume estimates.
- Development of a novel animal model to differentiate radiation necrosis from tumor recurrence.
- A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma.
- Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab.
- Angiogenesis and apoptosis in glioma: two arenas for promising new therapies.
- Optimization of high grade glioma cell culture from surgical specimens for use in clinically relevant animal models and 3D immunochemistry.
- Outcome prediction in patients with glioblastoma by using imaging, clinical, and genomic biomarkers: focus on the nonenhancing component of the tumor.
- Machine-based morphologic analysis of glioblastoma using whole-slide pathology images uncovers clinically relevant molecular correlates.
- Preclinical characterization of signal transducer and activator of transcription 3 small molecule inhibitors for primary and metastatic brain cancer therapy.
- Mechanisms of glioma formation: iterative perivascular glioma growth and invasion leads to tumor progression, VEGF-independent vascularization, and resistance to antiangiogenic therapy.
- Phase I and pharmacokinetic study of COL-3 in patients with recurrent high-grade gliomas.
- Gliosarcoma stem cells undergo glial and mesenchymal differentiation in vivo.
- Patterns of failure after radiosurgery to two different target volumes of enhancing lesions with and without FLAIR abnormalities in recurrent glioblastoma multiforme.
- Key determinants of short-term and long-term glioblastoma survival: a 14-year retrospective study of patients from the Hermelin Brain Tumor Center at Henry Ford Hospital.
- Altered adenosine-to-inosine RNA editing in human cancer.
- Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial.
- The selective Aurora-A kinase inhibitor MLN8237 (alisertib) potently inhibits proliferation of glioblastoma neurosphere tumor stem-like cells and potentiates the effects of temozolomide and ionizing radiation.
- A quantitative model of tumor-induced angiogenesis in the nude mouse.
- The role of salvage reirradiation for malignant gliomas that progress on bevacizumab.
- Correlation of immunohistologic and perfusion vascular parameters with MR contrast enhancement using image-guided biopsy specimens in gliomas.
- Cilengitide-induced temporal variations in transvascular transfer parameters of tumor vasculature in a rat glioma model: identifying potential MRI biomarkers of acute effects.
- NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme.
- Mesenchymal stem cells deliver synthetic microRNA mimics to glioma cells and glioma stem cells and inhibit their cell migration and self-renewal.
- Proteasome inhibitors sensitize glioma cells and glioma stem cells to TRAIL-induced apoptosis by PKCε-dependent downregulation of AKT and XIAP expressions.
- Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study.
- Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma.
- Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response.
- Initial experience with bevacizumab treatment for biopsy confirmed cerebral radiation necrosis.
- Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma.
- Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11.
- High-resolution global genomic survey of 178 gliomas reveals novel regions of copy number alteration and allelic imbalances.
- Differentiating treatment-induced necrosis from recurrent/progressive brain tumor using nonmodel-based semiquantitative indices derived from dynamic contrast-enhanced T1-weighted MR perfusion.
- Salvage reirradiation for recurrent glioblastoma with radiosurgery: radiographic response and improved survival.
- FK506 binding protein mediates glioma cell growth and sensitivity to rapamycin treatment by regulating NF-kappaB signaling pathway.
- Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme.
- Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study.
- Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain.
- Phase II preradiation R115777 (tipifarnib) in newly diagnosed GBM with residual enhancing disease.
- Phase I/II dose escalation trial of concurrent temozolomide and whole brain radiation therapy for multiple brain metastasis.
- Polynuclear platinum anticancer drugs are more potent than cisplatin and induce cell cycle arrest in glioma.
- A phase I/II trial and pharmacokinetic study of ixabepilone in adult patients with recurrent high-grade gliomas.
- GRP78 is overexpressed in glioblastomas and regulates glioma cell growth and apoptosis.
- The effect of enzyme-inducing antiseizure drugs on the pharmacokinetics and tolerability of procarbazine hydrochloride.
- Increased chemotactic migration and growth in heparanase-overexpressing human U251n glioma cells.
- and irinotecan treatment for progressive diffuse brainstem glioma: case report.
- Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma.
- Genomic changes and gene expression profiles reveal that established glioma cell lines are poorly representative of primary human gliomas.
- Cloning and characterization of human RTVP-1b, a novel splice variant of RTVP-1 in glioma cells.
- SDF-1 and CXCR4 are up-regulated by VEGF and contribute to glioma cell invasion.
- A simplified laboratory validated assay for MGMT promoter hypermethylation analysis of glioma specimens from formalin-fixed paraffin-embedded tissue.
- Insulin-like growth factor binding protein 7 mediates glioma cell growth and migration.
- Imaging response criteria for recurrent gliomas treated with bevacizumab: role of diffusion weighted imaging as an imaging biomarker.
- Decrease of endogenous vascular endothelial growth factor may not affect glioma cell proliferation and invasion.
- Phase 2 trial of copper depletion and penicillamine as antiangiogenesis therapy of glioblastoma.
- AMP-dependent protein kinase alpha 2 isoform promotes hypoxia-induced VEGF expression in human glioblastoma.
- Neurath KM, Keough MP, Mikkelsen T, Claffey KP.
- Can permeability measurements add to blood volume measurements in differentiating tumefactive demyelinating lesions from high grade gliomas using perfusion CT?
- Phase II clinical and pharmacologic study of radiation therapy and carboxyamido-triazole (CAI) in adults with newly diagnosed glioblastoma multiforme.
- Increased expression of thymidylate synthetase (TS), ubiquitin specific protease 10 (USP10) and survivin is associated with poor survival in glioblastoma multiforme (GBM).
- Assessment of brain tumor angiogenesis inhibitors using perfusion magnetic resonance imaging: quality and analysis results of a phase I trial.
- Akella NS, Twieg DB, Mikkelsen T, Hochberg FH, Grossman S, Cloud GA, Nabors LB.
- The role of emerging and investigational therapies for metastatic brain tumors: a systematic review and evidence-based clinical practice guideline of selected topics.
- A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting.
- 2D/3D image fusion for accurate target localization and evaluation of a mask based stereotactic system in fractionated stereotactic radiotherapy of cranial lesions.
- Associations among magnetic resonance spectroscopy, apparent diffusion coefficients, and image-guided histopathology with special attention to radiation necrosis.
- Degradation of extracellular matrix protein tenascin-C by cathepsin B: an interaction involved in the progression of gliomas.
- Poor drug distribution as a possible explanation for the results of the PRECISE trial.
- Correlations between magnetic resonance spectroscopy and image-guided histopathology, with special attention to radiation necrosis.
- Rock JP, Hearshen D, Scarpace L, Croteau D, Gutierrez J, Fisher JL, Rosenblum ML, Mikkelsen T.
- Phase I safety study of escalating doses of atrasentan in adults with recurrent malignant glioma.
- Phuphanich S, Carson KA, Grossman SA, Lesser G, Olson J, Mikkelsen T, Desideri S, Fisher JD; New Approaches to Brain Tumor Therapy (NABTT) CNS Consortium.
- First-pass perfusion computed tomography: initial experience in differentiating recurrent brain tumors from radiation effects and radiation necrosis.
- Cerebellar tumors in pediatric patients: can they be differentiated using diffusion-weighted imaging?
- Jain R, Mikkelsen T.
- Analysis of glioma cell platinum response by metacomparison of two-dimensional chromatographic proteome profiles.
- Tumor vascular leakiness and blood volume estimates in oligodendrogliomas using perfusion CT: an analysis of perfusion parameters helping further characterize genetic subtypes as well as differentiate from astroglial tumors.
- Studying the heterogeneity of brain tumors using medium throughput LOH analysis.
- Brain Tumors
- Clinical Trials
- Neuro Oncology
- Brain Tumors
- Glioma
- Neuro Oncology
- Neurofibroma
- Neurology Consultation